ProCE Banner Activity

Molecular Reclassification of Endometrial Cancer: Identifying Patients Eligible for Immunotherapy

Clinical Thought

Is immunotherapy suitable/appropriate for the treatment of endometrial cancer? Read my thoughts on why genetic profiling of endometrial cancer is important and which patients may benefit from single-agent immunotherapy or immunotherapy-based combinations.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: February 25, 2021

Expiration: February 24, 2022

Share

Faculty

Domenica Lorusso

Domenica Lorusso, MD, PhD, Prof

Full Professor of Obstetrics and Gynecology
Humanitas University
Head of Gynecology Oncology Medical Unit
Humanitas Hospital San Pio X
Milan, Italy

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Domenica Lorusso, MD, PhD, Prof

Full Professor of Obstetrics and Gynecology
Humanitas University
Head of Gynecology Oncology Medical Unit
Humanitas Hospital San Pio X
Milan, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.